COVID-19 Vaccines Show Efficiency in Thoracic Cancer Patients

Strategic Insights -

Researchers conducted a prospective vaccine monitoring study to assess the humoral responses to the SARS-CoV-2 vaccine in thoracic cancer patients. The study included 306 patients, with a median age of 67.0 years, who received two doses of the BNT162b2 mRNA vaccine. The results showed that 6.3% of patients still had negative serology beyond Day 14 post-second vaccine dose, but after a third vaccine dose, 88% of patients with persistent low antibody titers showed immunization.

Key Takeaways:

  • The study included 306 thoracic cancer patients with a median age of 67.0 years.
  • 283 patients received two vaccine doses at 28-day intervals.
  • After a median follow-up of 4.7 months, 7 patients (2.3%) contracted symptomatic SARS-CoV-2 infection, with a rapid favorable evolution.
  • 17 patients (6.3%) had negative serology beyond Day 14 post-second vaccine dose, indicating a lack of immunization.
  • In multivariate analysis, only age and chronic corticosteroid treatment were significantly associated with a lack of immunization.
  • A third vaccine shot was administered to 30 patients with persistent low antibody titers, resulting in a 88% immunization rate.
  • The study showed that the SARS-CoV-2 vaccine was efficient in thoracic cancer patients, with most patients being immunized after two doses.
  • The study's findings have important implications for the management of thoracic cancer patients during the COVID-19 pandemic.

Statistics:

  • 306 patients were included in the study.
  • The median age of patients was 67.0 years (IQR=58-74).
  • 283 patients received two vaccine doses at 28-day intervals.
  • 7 patients (2.3%) contracted symptomatic SARS-CoV-2 infection.
  • 17 patients (6.3%) had negative serology beyond Day 14 post-second vaccine dose.
  • 30 patients received a third vaccine dose, with 88% showing immunization after a third shot.

Sources:

  • medrxiv.org/content/10.1101/2021.08.12.21261806v1